Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.

摘要: Between 1978-1987, 439 patients with primary cervical carcinoma were admitted to our department. Seventy-seven (17.5%) had adenocarcinoma and are reviewed in this retrospective study. Serial serum samples of these 77 analyzed for cancer antigen 125 (CA 125), squamous cell antigen, carcinoembryonic antigen. Before treatment, only elevated CA levels varied directly the clinical stage disease. In stages IB II disease (International Federation Gynecology Obstetrics [FIGO]), incidence was highest adenosquamous tumor. Serum marker levels, measured 3 months after therapy, concurred treatment results. At that time, 17 23 cases (74%) at least one level either residual (N = 9) or developed recurrent during follow-up 8), compared six 40 (15%) normal (P less than .001). Increasing coincided preceded detection Tumor relapse, clinically located vaginal vault, occurred concomitant a rise seven (86%). All 15 abdominal recurrence showed elevation 125. progressive disease, very high 125, determined tumor, whereas demonstrated levels. We conclude all three markers important monitoring adenocarcinoma.